Effect of New Oral Treatment for Hepatitis C Virus on Seminal Parameters

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05616598

Enrollment

200

Registered

2022-11-15

Start date

2022-03-01

Completion date

2022-12-31

Last updated

2023-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HCV, Male Infertility

Keywords

Semen, DAA, Male infertility

Brief summary

Hepatitis C virus is commona viral infection. Direct-acting antiviral (DAA) oral drugs has been used in treatment of HCVs. the effect of these drugs on male infertility is still under investigation.

Detailed description

Semen analysis will be done to male patients with HCV before and after treatment with DAA. The included men will take therapy for 3 months and HCV RNA titter will be evaluated. changes of seminal parameters will be recorded and analyzed.

Interventions

DRUGSofosbuvir +daclatasvir+ simeprevir+Ribavirin

Oral daily dose of Sofosbuvir +daclatasvir + simeprevir+ Ribavirin for 3 months

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Intervention model description

DAA oral therapy for HCV.

Eligibility

Sex/Gender

MALE

Age

18 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

Men patients with HCV

Exclusion criteria

Patients with other hepatic disease, endocrinal disorder, malignancy, or urinary tract infection.

Design outcomes

Primary

Measure	Time frame	Description
Treatment of HCV	3 months	HCV titer by PCR is below detection level

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026